M. A. Murshid, Z. Mohaidin, Mohammad Zayed, Mohammed A. Al Doghan
Trustworthiness (TRS) is an essential factor that drives pharmacist–physician collaboration (PPC), which, in turn, improves prescribing behaviour. This study examines the moderating effect of TRS on the relationship between pharmacist expertise, PPC and prescribing decisions of physicians (PPD). A total of 393 usable data were collected from selected physicians using a structured questionnaire form. Partial least squares structural equation modelling was adopted for data analysis. The result shows that TRS does not moderate the relationship between pharmacist expertise power and PPD, although the relationship is stronger with higher TRS (β = 0.054, t = 0.483, P > 0.05). As expected, the relationship between PPC and PPD is stronger at high TRS (β = 0.137, t = 1.653, P < 0.05). TRS plays a ‘dynamic’ role in strengthening the positive impact of high pharmacist collaboration on prescribing rather than a ‘supportive’ role in increasing physicians’ readiness to gather information and recommendations from the pharmacist.
{"title":"Moderating effects of trustworthiness between pharmacists and physicians: using partial least squares","authors":"M. A. Murshid, Z. Mohaidin, Mohammad Zayed, Mohammed A. Al Doghan","doi":"10.1093/jphsr/rmab048","DOIUrl":"https://doi.org/10.1093/jphsr/rmab048","url":null,"abstract":"\u0000 \u0000 \u0000 Trustworthiness (TRS) is an essential factor that drives pharmacist–physician collaboration (PPC), which, in turn, improves prescribing behaviour. This study examines the moderating effect of TRS on the relationship between pharmacist expertise, PPC and prescribing decisions of physicians (PPD).\u0000 \u0000 \u0000 \u0000 A total of 393 usable data were collected from selected physicians using a structured questionnaire form. Partial least squares structural equation modelling was adopted for data analysis.\u0000 \u0000 \u0000 \u0000 The result shows that TRS does not moderate the relationship between pharmacist expertise power and PPD, although the relationship is stronger with higher TRS (β = 0.054, t = 0.483, P > 0.05). As expected, the relationship between PPC and PPD is stronger at high TRS (β = 0.137, t = 1.653, P < 0.05).\u0000 \u0000 \u0000 \u0000 TRS plays a ‘dynamic’ role in strengthening the positive impact of high pharmacist collaboration on prescribing rather than a ‘supportive’ role in increasing physicians’ readiness to gather information and recommendations from the pharmacist.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49131350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Zakeri, Jieni Li, Simin D Sadeghi, E. Essien, S. Sansgiry
Abstract Objectives This study aims to understand acceptable strategies to enhance the COVID-19 vaccine uptake among mothers who have no intention to vaccinate their children. Methods In a cross-sectional study, using an online survey in March 2021, we evaluated the variables within the Health Belief Model (severity, susceptibility, benefits, barriers and cues to action) along with parents’ sociodemographic characteristics, previous COVID-19 infection, job loss due to COVID-19 pandemic and the presence of healthcare workers among the household. Total number of children in the household and their chronic health conditions were also assessed. Multivariable logistic regression was performed to evaluate the intention to vaccinate children against the COVID-19 and associations with other variables. Key findings The survey response rate was 32.30% (595/1842). Most of the participants were White (72.1%), 31–40 years old (55.46%) and married or in a cohabiting relationship (90.25). Out of 595 mothers with 3–15 years old children, 38.32% had no intention to vaccinate their children. Top factors associated with intention were perceived susceptibility (P = 0.002), benefits (P < 0.001), barriers (P < 0.001), cues to action (P < 0.001) and the presence of healthcare workers in the household (P = 0.032). The main barriers were concerns about vaccine safety, efficacy and side effects. The strongest cue to action was enough information being provided followed by doctors’ recommendations. Conclusions Strategies to increase vaccination for children lie in the process of convincing parents with providing reliable information on the vaccine safety, efficacy and side effects by paediatricians and other healthcare providers.
{"title":"Strategies to decrease COVID-19 vaccine hesitancy for children","authors":"M. Zakeri, Jieni Li, Simin D Sadeghi, E. Essien, S. Sansgiry","doi":"10.1093/jphsr/rmab060","DOIUrl":"https://doi.org/10.1093/jphsr/rmab060","url":null,"abstract":"Abstract Objectives This study aims to understand acceptable strategies to enhance the COVID-19 vaccine uptake among mothers who have no intention to vaccinate their children. Methods In a cross-sectional study, using an online survey in March 2021, we evaluated the variables within the Health Belief Model (severity, susceptibility, benefits, barriers and cues to action) along with parents’ sociodemographic characteristics, previous COVID-19 infection, job loss due to COVID-19 pandemic and the presence of healthcare workers among the household. Total number of children in the household and their chronic health conditions were also assessed. Multivariable logistic regression was performed to evaluate the intention to vaccinate children against the COVID-19 and associations with other variables. Key findings The survey response rate was 32.30% (595/1842). Most of the participants were White (72.1%), 31–40 years old (55.46%) and married or in a cohabiting relationship (90.25). Out of 595 mothers with 3–15 years old children, 38.32% had no intention to vaccinate their children. Top factors associated with intention were perceived susceptibility (P = 0.002), benefits (P < 0.001), barriers (P < 0.001), cues to action (P < 0.001) and the presence of healthcare workers in the household (P = 0.032). The main barriers were concerns about vaccine safety, efficacy and side effects. The strongest cue to action was enough information being provided followed by doctors’ recommendations. Conclusions Strategies to increase vaccination for children lie in the process of convincing parents with providing reliable information on the vaccine safety, efficacy and side effects by paediatricians and other healthcare providers.","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43079721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Jha, Subish Palaian, Prabakaran Shankar, S. K. C., Pan Bahadur Kshetry
The aim of this study was to assess the national and regional pharmacovigilance centres in Nepal in terms of their policy frameworks, structure and functioning. A descriptive cross-sectional study was conducted during January 2021 among regional pharmacovigilance centres, and the national pharmacovigilance centre and the Ministry of Health and Population. The indicator-based pharmacovigilance assessment tool (IPAT) consisting of 43 indicators (26 core and 17 supplementary) assessing different aspects of pharmacovigilance was used. Of a total of 14 candidates representing regional pharmacovigilance centres, 12 agreed to participate. The national pharmacovigilance centre located at the Department of Drug Administration had an acceptable level of infrastructure and manpower but poor functioning and weak collaboration with regional centres. There are no policies and procedures specifically related to pharmacovigilance and no requirement for pharmaceutical companies to report adverse drug reactions (ADRs). The national centre received only 42 ADR reports during the evaluation period. The regional centres are mostly located (10 out of 14) in the Kathmandu Valley and had qualified manpower and basic resources. There were poor process indicators suggesting problems with functioning in terms of ADR reporting, signal generation and drug safety communication. Underreporting of ADRs, weak processes and poor coordination among centres limit functioning of the system. Creating more awareness, involving consumers and pharmaceutical companies in the reporting process, and conducting more training programmes are needed for the proper functioning of pharmacovigilance services in Nepal.
{"title":"Situation analysis of the pharmacovigilance system in Nepal using the indicator-based pharmacovigilance assessment tool (IPAT)","authors":"N. Jha, Subish Palaian, Prabakaran Shankar, S. K. C., Pan Bahadur Kshetry","doi":"10.1093/jphsr/rmab054","DOIUrl":"https://doi.org/10.1093/jphsr/rmab054","url":null,"abstract":"\u0000 \u0000 \u0000 The aim of this study was to assess the national and regional pharmacovigilance centres in Nepal in terms of their policy frameworks, structure and functioning.\u0000 \u0000 \u0000 \u0000 A descriptive cross-sectional study was conducted during January 2021 among regional pharmacovigilance centres, and the national pharmacovigilance centre and the Ministry of Health and Population. The indicator-based pharmacovigilance assessment tool (IPAT) consisting of 43 indicators (26 core and 17 supplementary) assessing different aspects of pharmacovigilance was used.\u0000 \u0000 \u0000 \u0000 Of a total of 14 candidates representing regional pharmacovigilance centres, 12 agreed to participate. The national pharmacovigilance centre located at the Department of Drug Administration had an acceptable level of infrastructure and manpower but poor functioning and weak collaboration with regional centres. There are no policies and procedures specifically related to pharmacovigilance and no requirement for pharmaceutical companies to report adverse drug reactions (ADRs). The national centre received only 42 ADR reports during the evaluation period. The regional centres are mostly located (10 out of 14) in the Kathmandu Valley and had qualified manpower and basic resources. There were poor process indicators suggesting problems with functioning in terms of ADR reporting, signal generation and drug safety communication.\u0000 \u0000 \u0000 \u0000 Underreporting of ADRs, weak processes and poor coordination among centres limit functioning of the system. Creating more awareness, involving consumers and pharmaceutical companies in the reporting process, and conducting more training programmes are needed for the proper functioning of pharmacovigilance services in Nepal.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48118124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yaran K Gonzalez Gonzalez, Kristen Yaun, Pooja Shah, G. Iglesias, G. Hale, N. Khanfar
Previous trials have confirmed a positive relationship between obesity and hypertension. The purpose of this article is to identify the impact of pharmacists in lifestyle adherence among obese, hypertensive patients. A literature search was performed at an academic institution using secondary databases, PubMed/MEDLINE and EBSCOhost. Reviews, observational and experimental reports published in English between 2010 and 2020 were included. Terms searched were pharmacy, pharmacist, lifestyle modifications, adherence, compliance, hypertension, obesity, consultation, intervention. Effect on lifestyle modifications consisted of change in blood pressure values, weight, body mass index, diet/sodium intake and/or exercise. Six hundred seventy-five articles were reviewed with 10 meeting inclusion criteria. The role of a pharmacist has a positive impact on compliance in lifestyle adherence with obese, hypertensive patients. Additionally, age, gender marital status, education, monthly income, knowledge level and beliefs of hypertension and co-morbidities all can affect adherence to lifestyle modifications. The pharmacist has a vital role in the management of hypertension and obesity through frequent interactions with patients to increase adherence to lifestyle modifications.
{"title":"A literature review of pharmacist’s impact on lifestyle modifications among obese, hypertensive patients","authors":"Yaran K Gonzalez Gonzalez, Kristen Yaun, Pooja Shah, G. Iglesias, G. Hale, N. Khanfar","doi":"10.1093/jphsr/rmab053","DOIUrl":"https://doi.org/10.1093/jphsr/rmab053","url":null,"abstract":"\u0000 \u0000 \u0000 Previous trials have confirmed a positive relationship between obesity and hypertension. The purpose of this article is to identify the impact of pharmacists in lifestyle adherence among obese, hypertensive patients.\u0000 \u0000 \u0000 \u0000 A literature search was performed at an academic institution using secondary databases, PubMed/MEDLINE and EBSCOhost. Reviews, observational and experimental reports published in English between 2010 and 2020 were included. Terms searched were pharmacy, pharmacist, lifestyle modifications, adherence, compliance, hypertension, obesity, consultation, intervention. Effect on lifestyle modifications consisted of change in blood pressure values, weight, body mass index, diet/sodium intake and/or exercise.\u0000 \u0000 \u0000 \u0000 Six hundred seventy-five articles were reviewed with 10 meeting inclusion criteria. The role of a pharmacist has a positive impact on compliance in lifestyle adherence with obese, hypertensive patients. Additionally, age, gender marital status, education, monthly income, knowledge level and beliefs of hypertension and co-morbidities all can affect adherence to lifestyle modifications.\u0000 \u0000 \u0000 \u0000 The pharmacist has a vital role in the management of hypertension and obesity through frequent interactions with patients to increase adherence to lifestyle modifications.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44688727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gülpembe Og˘uzhan, S. Ökçün, M. Kurnaz, G. Koçkaya, S. S¸en, Burçin Kahveci Kaplan, I˙˙smail Mete S¸aylan
{"title":"Corrigendum to: Determining the impact of vitamin C use with the common cold on loss of labour and medical treatment costs for Turkey","authors":"Gülpembe Og˘uzhan, S. Ökçün, M. Kurnaz, G. Koçkaya, S. S¸en, Burçin Kahveci Kaplan, I˙˙smail Mete S¸aylan","doi":"10.1093/jphsr/rmab052","DOIUrl":"https://doi.org/10.1093/jphsr/rmab052","url":null,"abstract":"","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":"221 3","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41258862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Suppiah, Fiona S. Kelly, Oliver Watt, A. Wheeler, E. Hotham, S. McMillan
Abstract Objectives This study aimed to explore the range of activities provided by community pharmacists for promoting mental well-being in Australia. Methods An online survey was developed and piloted by 2 community pharmacists, 1 representative from the Pharmaceutical Society of Australia and 11 pharmacy students for content and face validity. Community pharmacists were recruited via direct emails to pharmacy groups and social media between November 2019 and January 2020. Descriptive statistics and chi-squared analyses were conducted. Key findings Data were analysed from 85 pharmacists (of 115 total pharmacy staff respondents). Although 40% reported working in a pharmacy that promoted mental well-being, most (88.2%) were not involved in such activities. However, most respondents (88.0%) identified community pharmacy as a suitable setting to promote mental well-being. Barriers to mental well-being promotion included busy pharmacy environment with competing priorities, a lack of staff training and confidence in discussing mental well-being and stigma associated with mental illness. Conclusions Community pharmacy presents a suitable setting to promote mental well-being. However, pharmacists may not be utilizing their full range of skills and knowledge in promoting a national health priority. This study identified opportunities for increased pharmacist-led promotion of mental well-being, particularly given the emerging mental health impacts of the COVID-19 pandemic. The pandemic has highlighted the growing urgency for mental health-friendly health workers across the sector including the community pharmacy workforce to engage consumers about their mental well-being.
{"title":"Mental well-being promotion by Australian community pharmacists: what’s happening and what needs to be done?","authors":"V. Suppiah, Fiona S. Kelly, Oliver Watt, A. Wheeler, E. Hotham, S. McMillan","doi":"10.1093/jphsr/rmab051","DOIUrl":"https://doi.org/10.1093/jphsr/rmab051","url":null,"abstract":"Abstract Objectives This study aimed to explore the range of activities provided by community pharmacists for promoting mental well-being in Australia. Methods An online survey was developed and piloted by 2 community pharmacists, 1 representative from the Pharmaceutical Society of Australia and 11 pharmacy students for content and face validity. Community pharmacists were recruited via direct emails to pharmacy groups and social media between November 2019 and January 2020. Descriptive statistics and chi-squared analyses were conducted. Key findings Data were analysed from 85 pharmacists (of 115 total pharmacy staff respondents). Although 40% reported working in a pharmacy that promoted mental well-being, most (88.2%) were not involved in such activities. However, most respondents (88.0%) identified community pharmacy as a suitable setting to promote mental well-being. Barriers to mental well-being promotion included busy pharmacy environment with competing priorities, a lack of staff training and confidence in discussing mental well-being and stigma associated with mental illness. Conclusions Community pharmacy presents a suitable setting to promote mental well-being. However, pharmacists may not be utilizing their full range of skills and knowledge in promoting a national health priority. This study identified opportunities for increased pharmacist-led promotion of mental well-being, particularly given the emerging mental health impacts of the COVID-19 pandemic. The pandemic has highlighted the growing urgency for mental health-friendly health workers across the sector including the community pharmacy workforce to engage consumers about their mental well-being.","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43627743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The market for innovative drugs is characterized by high levels of regulation, whose impact on the market is not neutral. On the one hand, strict regulation may in fact adversely affect incentives to develop new and better products; on the other hand, high prices may drive an unsustainable increase in healthcare costs. This trade-off is particularly important in Europe, where about 75% of drugs costs are financed by the public sector. We develop a simple model that allows to compare the impact of different listing and pricing strategies on the social value of innovative drugs, the consumer surplus and the expected profit of the industry. Uncertainty in the expected price, as well as other forms of access regulation, may lead to a fairer division of the social value between patients and the industry, at the cost of leaving some of the potential value of the drug unexploited. The regulator may improve value for money if it is prepared either to restrict access to the drug or to reduce the expected price. In both cases, the number of groups of patients treated may be different from the social optimum.
{"title":"Value-based drug price schemes: a welfare analysis","authors":"L. Levaggi, Rosella Levaggi","doi":"10.1093/jphsr/rmab043","DOIUrl":"https://doi.org/10.1093/jphsr/rmab043","url":null,"abstract":"The market for innovative drugs is characterized by high levels of regulation, whose impact on the market is not neutral. On the one hand, strict regulation may in fact adversely affect incentives to develop new and better products; on the other hand, high prices may drive an unsustainable increase in healthcare costs. This trade-off is particularly important in Europe, where about 75% of drugs costs are financed by the public sector. We develop a simple model that allows to compare the impact of different listing and pricing strategies on the social value of innovative drugs, the consumer surplus and the expected profit of the industry. Uncertainty in the expected price, as well as other forms of access regulation, may lead to a fairer division of the social value between patients and the industry, at the cost of leaving some of the potential value of the drug unexploited. The regulator may improve value for money if it is prepared either to restrict access to the drug or to reduce the expected price. In both cases, the number of groups of patients treated may be different from the social optimum.","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43369589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pharmacoeconomic dimensions linking clinical effectiveness of parenteral anticoagulants for management of acute venous thromboembolism (VTE) and cost of treatment are needed to support choices by healthcare providers. The objective of the study was to conduct a cost-effectiveness analysis for 5-day treatment with parenteral anticoagulants in Jordan. Cost-effectiveness analysis was conducted based on decision analysis tree model. The perspective was the payer, considering direct medical costs. Probabilities of failure of treatment and major bleeding were derived from published clinical studies. Costs were estimated based on 2019 prices in Jordan. The average cost of VTE hospitalization and major bleeding management in Jordan were 2324.00 US$ and 3347.40 US$, respectively. Bemiparin was associated with the highest clinical efficacy and lowest probability of major bleeding. Nadroparin had the lowest clinical efficacy, while tinzaparin was found to have the highest risk of major bleeding. Bemiparin had the lowest average cost-effectiveness ratio (101.63 US$/success) and nadroparin had the highest cost-effectiveness ratio (295.56 US$/success). Throughout the sensitivity analysis calculations, bemiparin and nadroparin had the lowest and highest cost of treatment, respectively. The cost of parenteral anticoagulant drugs, the same as many other drugs, does not always correlate with cost of VTE treatment. Other direct medical costs (e.g. treatment failure and management of bleeding) have a high contribution to the total cost calculation. Pharmacoeconomically, bemiparin is the dominant cost-effective parenteral anticoagulant in Jordan, while nadroparin is the dominated one.
{"title":"Cost-effectiveness analysis for the parenteral anticoagulants in Jordan","authors":"Shatha Alquraan, Feras Darwish El-Hajji","doi":"10.1093/jphsr/rmab045","DOIUrl":"https://doi.org/10.1093/jphsr/rmab045","url":null,"abstract":"\u0000 \u0000 \u0000 Pharmacoeconomic dimensions linking clinical effectiveness of parenteral anticoagulants for management of acute venous thromboembolism (VTE) and cost of treatment are needed to support choices by healthcare providers. The objective of the study was to conduct a cost-effectiveness analysis for 5-day treatment with parenteral anticoagulants in Jordan.\u0000 \u0000 \u0000 \u0000 Cost-effectiveness analysis was conducted based on decision analysis tree model. The perspective was the payer, considering direct medical costs. Probabilities of failure of treatment and major bleeding were derived from published clinical studies. Costs were estimated based on 2019 prices in Jordan.\u0000 \u0000 \u0000 \u0000 The average cost of VTE hospitalization and major bleeding management in Jordan were 2324.00 US$ and 3347.40 US$, respectively. Bemiparin was associated with the highest clinical efficacy and lowest probability of major bleeding. Nadroparin had the lowest clinical efficacy, while tinzaparin was found to have the highest risk of major bleeding. Bemiparin had the lowest average cost-effectiveness ratio (101.63 US$/success) and nadroparin had the highest cost-effectiveness ratio (295.56 US$/success). Throughout the sensitivity analysis calculations, bemiparin and nadroparin had the lowest and highest cost of treatment, respectively.\u0000 \u0000 \u0000 \u0000 The cost of parenteral anticoagulant drugs, the same as many other drugs, does not always correlate with cost of VTE treatment. Other direct medical costs (e.g. treatment failure and management of bleeding) have a high contribution to the total cost calculation. Pharmacoeconomically, bemiparin is the dominant cost-effective parenteral anticoagulant in Jordan, while nadroparin is the dominated one.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45023974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Chelghoum, W. Khitri, F. Kadouri, Khedra Chaouche
The objective of this study was to assess the needs for pharmaceutical services from the perspectives of physicians and patients in the hospital setting and to contribute to the implementation of new hospital pharmacy activities. A cross-sectional descriptive study was carried out among the doctors and patients encountered in hospital departments in Sidi Bel Abbès (Algeria); each service was evaluated using a Likert scale. Associated characteristics with an important need were evaluated by univariate analysis and binary logistic regression. All pharmaceutical services were important to the patients, particularly providing treatment advice and therapeutic education. Women presented an important need for insurance of the availability of pharmaceutical products (P = 0.02) and lifestyle and dietetic information (P = 0.05). High frequency of taking medication was associated with an important need for information about drug interactions (P = 0.005). Patient-oriented pharmaceutical services were not important to the physicians who considered drug information and therapeutic education to be the most important need. To implement patient-centred services, it is important to improve the contact between pharmacists and physicians and to provide information about pharmaceutical services that can benefit patients. Implementation of new practices in university hospital is more feasible than in public health facilities.
{"title":"A pilot study to assess the need for new hospital pharmaceutical services in Algerian patients and physicians’ perspective","authors":"M. Chelghoum, W. Khitri, F. Kadouri, Khedra Chaouche","doi":"10.1093/jphsr/rmab042","DOIUrl":"https://doi.org/10.1093/jphsr/rmab042","url":null,"abstract":"\u0000 \u0000 \u0000 The objective of this study was to assess the needs for pharmaceutical services from the perspectives of physicians and patients in the hospital setting and to contribute to the implementation of new hospital pharmacy activities.\u0000 \u0000 \u0000 \u0000 A cross-sectional descriptive study was carried out among the doctors and patients encountered in hospital departments in Sidi Bel Abbès (Algeria); each service was evaluated using a Likert scale. Associated characteristics with an important need were evaluated by univariate analysis and binary logistic regression.\u0000 \u0000 \u0000 \u0000 All pharmaceutical services were important to the patients, particularly providing treatment advice and therapeutic education. Women presented an important need for insurance of the availability of pharmaceutical products (P = 0.02) and lifestyle and dietetic information (P = 0.05). High frequency of taking medication was associated with an important need for information about drug interactions (P = 0.005). Patient-oriented pharmaceutical services were not important to the physicians who considered drug information and therapeutic education to be the most important need.\u0000 \u0000 \u0000 \u0000 To implement patient-centred services, it is important to improve the contact between pharmacists and physicians and to provide information about pharmaceutical services that can benefit patients. Implementation of new practices in university hospital is more feasible than in public health facilities.\u0000","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47917275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How to have a manuscript accepted for publication","authors":"A. Wertheimer","doi":"10.1093/jphsr/rmab032","DOIUrl":"https://doi.org/10.1093/jphsr/rmab032","url":null,"abstract":"","PeriodicalId":16705,"journal":{"name":"Journal of Pharmaceutical Health Services Research","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43556779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：